Reata Pharmaceuticals Inc
NASDAQ:RETA
Intrinsic Value
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. [ Read More ]
The intrinsic value of one RETA stock under the Base Case scenario is 73.26 USD. Compared to the current market price of 172.36 USD, Reata Pharmaceuticals Inc is Overvalued by 57%.
Valuation Backtest
Reata Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling RETA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Reata Pharmaceuticals Inc
Current Assets | 401.8m |
Cash & Short-Term Investments | 330.2m |
Receivables | 22.7m |
Other Current Assets | 49m |
Non-Current Assets | 100.7m |
PP&E | 89.9m |
Other Non-Current Assets | 10.8m |
Current Liabilities | 125.1m |
Accounts Payable | 19.9m |
Accrued Liabilities | 27.6m |
Other Current Liabilities | 77.6m |
Non-Current Liabilities | 290.2m |
Long-Term Debt | 73.1m |
Other Non-Current Liabilities | 217.1m |
Earnings Waterfall
Reata Pharmaceuticals Inc
Revenue
|
23.5m
USD
|
Cost of Revenue
|
-1.6m
USD
|
Gross Profit
|
21.9m
USD
|
Operating Expenses
|
-363.6m
USD
|
Operating Income
|
-341.7m
USD
|
Other Expenses
|
254m
USD
|
Net Income
|
-87.6m
USD
|
Free Cash Flow Analysis
Reata Pharmaceuticals Inc
What is Free Cash Flow?
RETA Profitability Score
Profitability Due Diligence
Reata Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Reata Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
RETA Solvency Score
Solvency Due Diligence
Reata Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Reata Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RETA Price Targets Summary
Reata Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for RETA is 172.4 USD .
Ownership
RETA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RETA Price
Reata Pharmaceuticals Inc
Average Annual Return | 14.98% |
Standard Deviation of Annual Returns | 130.2% |
Max Drawdown | -92% |
Market Capitalization | 6.5B USD |
Shares Outstanding | 37 553 034 |
Percentage of Shares Shorted | 8.14% |
RETA News
Last Important Events
Reata Pharmaceuticals Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Reata Pharmaceuticals Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 346 full-time employees. The company went IPO on 2016-05-26. The firm is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. The company is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.
Contact
IPO
Employees
Officers
The intrinsic value of one RETA stock under the Base Case scenario is 73.26 USD.
Compared to the current market price of 172.36 USD, Reata Pharmaceuticals Inc is Overvalued by 57%.